GCDFP-15 Antibodies

Santa Cruz Biotechnology features a diverse variety of GCDFP-15 monoclonal antibodies for research in the field of breast cancer and related studies. GCDFP-15 Antibodies are validated for various techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). GCDFP-15, or glandular differentiation factor 15, is a protein that plays a significant role in the differentiation of mammary gland cells and serves as a biomarker in breast cancer diagnosis and prognosis. GCDFP-15 expression is associated with various stages of breast cancer, making it an important target for understanding tumor biology and developing therapeutic strategies. The study of GCDFP-15 can provide insights into the mechanisms of breast cancer progression and potential treatment options. Research focusing on GCDFP-15 has revealed its potential as a diagnostic tool and therapeutic target in breast cancer management. Understanding GCDFP-15 expression patterns helps researchers identify specific breast cancer subtypes and develop targeted treatments. Investigating GCDFP-15's role in cancer development has opened new avenues for therapeutic intervention. Santa Cruz Biotechnology monoclonal antibodies targeting GCDFP-15 enable researchers worldwide to advance our understanding of breast cancer biology and contribute to the development of more effective treatments.